Management of breast cancer in the genome era.
The genomic era has been characterized by an exponential increase in the number of targets in the management of breast cancer. Prognostic profiling has helped to determine which tumors are more likely to be associated with poor disease-free survival. Gene expression profiles are being studied in order to improve predictions of response and toxicity. Epigenetics is being evaluated for its ability to influence estrogen receptor expression. However, these fields require further validation. This review discusses the advances in the management of breast cancer through genomic evaluation.
Morrow
Phuong Khanh H
PK
Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
Hortobagyi
Gabriel N
GN
D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics*; D005260:Female; D023281:Genomics; D006801:Humans; D011379:Prognosis